Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02787044 · ClinicalTrials.gov registry record · Phase 4
INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure
A Phase 4 study of Heart Failure and Myocardial Infarction, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 5,388
- Enrollment target
- 20
- Study locations
NCT02787044 is a Phase 4 study of Heart Failure and Myocardial Infarction that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 5,388 participants, above the 2,035-participant average among 397 other Heart Failure trials with a reported enrollment target (165% higher). The trial reports 20 study locations across 8 states.
The verdict
NCT02787044, a Phase 4 study of Heart Failure and Myocardial Infarction, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 5,388 participants
- Enrollment target
- 20
- Study locations
Study Summary
INVESTED will test the hypothesis that high dose trivalent influenza vaccine will reduce cardiopulmonary events to a greater extent than standard dose quadrivalent influenza vaccine in high-risk cardiovascular patients with a recent history of myocardial infarction or heart failure. The trial will enroll 9300 participants over one Vanguard (pilot) season and three additional influenza seasons. The primary endpoint will be a composite of all-cause mortality or cardiopulmonary hospitalization.
Conditions Studied
Interventions
- BIOLOGICAL High Dose Trivalent Influenza Vaccine
- BIOLOGICAL Standard Dose Quadrivalent Influenza Vaccine
Study Locations (20)
Florida
- Clearwater Cardiovascular Consultants - Clearwater
- N FL/S GA Veterans Health System - Gainesville
- OneFlorida CDRN - Gainesville
- Clearwater Cardiovascular Consultants-Largo - Largo
- Inpatient Research Corporation - Miami
- ITB Research - Miami
California
- VA Loma Linda Healthcare System - Loma Linda
- Long Beach VAMC - Long Beach
- University of California Davis Medical Center - Sacramento
- VA San Diego Healthcare System - San Diego
- UCSF Medical Center - San Francisco
Alabama
- Birmingham VAMC - Birmingham
- University of Alabama Hypertension Program - Birmingham
- Heart Center Research, LLC - Huntsville
Arizona
- Banner University Medicine North - Tucson
- University of Arizona- Sarver Heart Center - Tucson
Alaska
- Alaska Heart & Vascular Institute - Anchorage
Arkansas
- CAVHS - Little Rock
Connecticut
- VA West Haven - West Haven
District of Columbia
- Washington DC VAMC - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,388 participants |
| Start Date | 2016-08-01 |
| Est. Completion | 2020-05-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02787044
The ClinicalTrials.gov registry entry for NCT02787044 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 5,388 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 2,035-participant average among 397 other Heart Failure trials with a reported enrollment target (165% higher). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Heart Failure appearing as the primary indexed condition, and to 2 interventions - of which High Dose Trivalent Influenza Vaccine is the first listed.
NCT02787044 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Florida, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT02787044 about?
NCT02787044 is a clinical study titled "INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure". INVESTED will test the hypothesis that high dose trivalent influenza vaccine will reduce cardiopulmonary events to a greater extent than standard dose quadrivalent influenza vaccine in high-risk cardiovascular patients with a recent history of myocardial infarction or heart failure. The trial will e...
What is the current status of trial NCT02787044?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 5,388 participants. The study started on 2016-08-01. Estimated completion is 2020-05-31.
What conditions does trial NCT02787044 study?
This clinical trial studies the following conditions: Heart Failure, Myocardial Infarction.
What interventions are being tested in trial NCT02787044?
The interventions under investigation include: High Dose Trivalent Influenza Vaccine (BIOLOGICAL), Standard Dose Quadrivalent Influenza Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT02787044?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02787044 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Gator SCALES-WHF: SubCutaneous Administration of Lasix to Eliminate Symptoms of Worsening Heart Failure
RECRUITING · Phase 4
-
Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure
RECRUITING · Phase 4
-
Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure
RECRUITING · Phase 4
-
The STOP-MED CTRCD Trial
RECRUITING · Phase 4
-
IRONICA: IRON Repletion In Heart Failure - A Comparison of Oral and IV Approaches
RECRUITING · Phase 4
-
Efficacy Of Sodium Glucose Transporter Inhibitor (SGLT2I) In Adult Patients With Congenital Heart Disease
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.